Why our TAVR will win

This is an interesting recent article on a TAVR trial for younger, lower risk cohorts. I think it really highlights the issues that current TAVR’s face and shines a light on our competitive and unique advantage. Our single piece valve already shown to be 10 years calcification free, toxic chemical free and stronger than our own native valves.

The prospect of a TAVR co development partnership is very real and will shock the market if it happens. The current share price basically ascribes zero value to this while companies in phase 1 and phase 2 trials with equal or smaller TAM’s are valued at multiples of Admedus. This will truely be a very exciting year for all stakeholders and patients alike.

Some excepts here and the article link below.

“Session panelist Neil Moat, MBBS, of Royal Brompton Hospital in London, said he found it worrying that there was a signal of structural valve failure at a time when TAVR is moving toward younger, lower-risk patients.”

“Before TAVR becomes widely adopted for lower and lower risk patients, clinicians have to understand the long-term durability of these valves, he said, noting that most of the low-risk studies that are currently underway are planned to continue to follow the patients for at least 10 years.”

https://www.medpagetoday.com/meetingcoverage/crt/71549